BPG is committed to discovery and dissemination of knowledge
Number of total visits
2737629
Number of visits today
566
Number of downloads
2008993
MEMBERSHIP
Cited by in F6Publishing
Number
Citing Articles
1
Guo F , Wang H . Potential of histone deacetylase inhibitors for the therapy of ovarian cancer. Front Oncol 2022;12 :1057186. [PMID: 36505774 DOI: 10.3389/fonc.2022.1057186 ] [ Reference Citation Analysis ]
2
Jia L , Gao Z, Chen J. High levels of m6A methylation and histone acetylation modification patterns contribute to the survival of LUAD patients.. [DOI: 10.21203/rs.3.rs-2199422/v1 ] [ Reference Citation Analysis ]
3
Hu X , Zhang X, Li S, Hua T. Construction and validation of a histone acetylation-related lncRNA prognosis signature for ovarian cancer. Front Genet 2022;13 :934246. [DOI: 10.3389/fgene.2022.934246 ] [ Reference Citation Analysis ]
4
Zhao Y , Zhang Y, Dai C, Hong K, Guo Y. A signature constructed with mitophagy-related genes to predict the prognosis and therapy response for breast cancer. Aging . [DOI: 10.18632/aging.204209 ] [ Cited by in Crossref: 2] [ Cited by in F6Publishing: 2 ] [ Article Influence: 2.0 ] [ Reference Citation Analysis ]
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345